• Explore /
  • Poster
  • / Nivolumab timing as a major survival predictor in patients with stage IV non–small cell lung cancer.

Nivolumab timing as a major survival predictor in patients with stage IV non–small cell lung cancer.

Abstract Poster

Authors

null

Abdoulaye Karaboué

Medical Oncology Unit, GHT Grand Paris Est, Montfermeil Hospital, Montfermeil, France

Abdoulaye Karaboué , Thierry Collon , Viviane Bodiguel , Joel Cucherousset , Pasquale Innominato , Mohamed Bouchahda , Rene Adam , Francis Levi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9058)

DOI

10.1200/JCO.2022.40.16_suppl.9058

Abstract #

9058

Poster Bd #

46

Abstract Disclosures

Similar Posters

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

First Author: Laurent Mhanna

First Author: David Paul Carbone

First Author: Panpan Zhang

First Author: Kohei Shitara